| Vol. 13.09 – 20 March, 2024 |
| |
|
|
| Site-specific phosphorylation of PHF8 orchestrated epigenetic changes that upregulate cytosolic RNA sensors, particularly the TRIM25-RIG-I-IFIT5 axis, thereby triggering the cellular IFN-I response-differentiation-apoptosis network. [Blood] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists constructed a bio-responsive Au-miR-183 inhibitor delivery system targeting liver CSCs, and adopted the strategy of combining αPD-L1 immunotherapy. [Journal Of Controlled Release] |
|
|
|
| Investigators showed that the triggering receptor expressed on myeloid cells-1 (TREM1) preferentially expressed by M2-like tumor-associated macrophages and induced glioma stem cells into mesenchymal-like states by modulating the secretion of TGFβ2. [Cancer Letters] |
|
|
|
| The authors used transcriptomic analysis along with in vitro and in vivo models of RAS/RAF wild-type CRC to study YAP1 Ser397 phosphorylation as a potential biomarker for cetuximab resistance. [British Journal Of Cancer] |
|
|
|
| Scientists employed microfluidic single-cell culture arrays to expand renal cancer stem cells by exploiting the anti-apoptosis and self-renewal properties of tumor stem cells. [Lab On A Chip] |
|
|
|
| Leukemia inhibitory factor-treated gastric cancer cell lines, patient-derived xenograft cells and/or CSC tumourspheres underwent transcriptomics, laser microdissection-associated proteomics, 2D and 3D invasion assays and in vivo xenograft in mice blood circulation. [Cell Death Discovery] |
|
|
|
| Investigators treated pancreatic tumor organoids with 4 or 8 Gy of radiation, 10 μM of 5-Fluorouracil, and 100 μM 3-Bromopyruvate, a promising anti-cancer drug, as a single treatment modalities, and in combination with RT. [Cell Death Discovery] |
|
|
|
| The bi-nuclear copper(II) complex exhibited sub-micromolar potency towards breast CSCs grown in monolayers and three-dimensional cultures. [Dalton Transactions] |
|
|
|
| The authors constructed a series of in vitro experiments, including 3D non-adherent sphere-formation, cytometry analysis, assessment of CSC marker expression, cell migration assay, and in vivo tumorigenesis analyses. [Heliyon] |
|
|
|
|
| Investigators provide an outlook into next-generation bispecific antibodies (bsAbs) in earlier stages of development, including trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumour targets and bsAbs acting as cytokine mimetics. [Nature Reviews Drug Discovery] |
|
|
|
| Scientists provide an overview of the recent advancements in understanding ferroptosis in cancer, covering molecular mechanisms, biological functions, regulatory pathways, and interactions with the tumor microenvironment. [Signal Transduction And Targeted Therapy] |
|
|
|
|
| The American Association for Cancer Research has awarded Dr. Owen Witte, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, with the 2024 Award for Outstanding Achievement in Blood Cancer Research. [UCLA] |
|
|
|
| Prostate cancer research team including Drs. Roseline Godbout, Adam Kinnaird, and Ron Moore have been awarded a $1.25 million, four-year Alberta Cancer Foundation “Game Changer Grant” to investigate the link between fat metabolism and prostate cancer progression. [University of Alberta] |
|
|
|
|
| April 24 – 26, 2024 Vienna, Austria |
|
|
|
|
|
| Universitätsklinikum Köln – Cologne, Germany |
|
|
|
| Francis Crick Institute – London, England, United Kingdom |
|
|
|
| University of Montpellier – Montpellier, France |
|
|
|
| Foundation for Liver Research – London, England, United Kingdom |
|
|
|
| Georg-Speyer-Haus – Frankfurt, Germany |
|
|
|
|